BridgeBio Pharma, Inc.
NASDAQBridgeBio Pharma heads into the final stretch of Q2 with its strongest monthly gain in recent memory — but one corner of the market is turning sharply defensive just as the tape improves. The stock closed at $74.48 on June 30, up 8.5% on the week and 12.4% over the past month. That rally places BBIO comfortably ahead of several correlated peers: VRTX gained 6% on the…
BBIO put-call ratio spikes to 0.60, highest in 52 weeks, signaling extreme options bearishness—4.3 standard deviations above the 20-day mean of 0.20.
BridgeBio Pharma heads into the final stretch of Q2 with its strongest monthly gain in recent memory — but one corner of the market is turning sharply defensive just as the tape improves. The stock closed at $74.48 on…
BridgeBio Pharma heads into its June 22 earnings date with a notable split: the options market has swung back to bullish extremes, the lending pool is flush, and fresh analyst initiations are clustering above current…
Snapshot as of 12 Jul 2026
BridgeBio Pharma enters the final stretch before its June 22 earnings with a cluster of insider sales at the top, a dramatic single-day shift in options sentiment, and a short position that — while elevated — has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BBIO — free to start on ORTEX.
Sign up for free →Open BBIO on ORTEX